Survival after HeartMate 3 left ventricular assist device implantation: real‐world data from Europe

Table 1 Baseline demographics of all primary HeartMate 3 implantations in all three included centres compared to MOMENTUM characteristics Variable Total (n = 377) UMCU (n = 80) HDZ NRW (n = 194) MedUni Vienna (n = 103) MOMENTUM 3 (n = 515) Age, median (IQR), years 60 (52–66) 56 (47–61) 60 (53–66) 64 (56–68) 62 (52–68) Sex (% male) 315 (83.6) 52 (65.0) 171 (88.1) 92 (89.3) 410 (79.6) BSA, mean (SD), m2 2.03 (0.21) 1.98 (0.23) 2.05 (0.20) 2.03 (0.20) 2.07 (0.27) BMI, median (IQR), kg/m2 25.7 (23.1–29.4) 24.7 (21.6–27.8) 25.7 (23.6–29.6) 27.2 (24.2–31.2) 28.4 (24.6–33.0) Ischemic CMP (%) 185 (49.1) 19 (23.8) 98 (50.5) 68 (66.0) 216 (41.9) Diabetes (%) 109 (30.0) 12 (15.0) 63 (35.0) 34 (33.0) 233 (45.2) Stroke (%) 32 (8.8) 3 (3.8) 21 (11.7) 8 (7.8) 50 (9.7) eGFR (mL/min/1.73 m2) 51 (36–70) 61 (43–83) 53 (36–78) 41 (32–53) 58 (43–75) INTERMACS (%) 1–2 198 (52.5) 41 (51.2) 114 (58.8) 43 (41.7) 167 (32.5) 3 98 (26.0) 21 (26.2) 56 (28.9) 21 (20.4) 272 (52.9) 4–7 81 (21.5) 18 (22.5) 24 (12.4) 39 (37.9) 75 (14.6) IABP (%) 8 (2.1) 1 (1.2) 6 (3.1) 1 (1.0) 64 (12.4) BMI, body mass index; BSA, body surface area; CMP, cardiomyopathy; eGFR, estimated glomerular filtration rate; HDZ NRW, Heart and Diabetes Centre North Rhine-Westphalia; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; MedUni Vienna, Medical University of Vienna; UMCU, University Medical Centre Utrecht. LVAD patients awaiting a donor heart in the United States have a shorter median duration of LVAD support and a higher frequency of comorbid conditions when compared to patients in Europe. 3 Despite differences in patient selection and donor heart availability, long-term survival after HM3 implantation is comparable. [...]real-world data from patients on HM3 support implanted in Europe confirm the promising findings of the MOMENTUM 3 trial, demonstrating the vital role of LVAD therapy in contemporary treatment of advanced heart failure.